MX2019008949A - Agente terapeutico para cardiomiopatia, infarto al miocardio antiguo e insuficiencia cardiaca cronica. - Google Patents
Agente terapeutico para cardiomiopatia, infarto al miocardio antiguo e insuficiencia cardiaca cronica.Info
- Publication number
- MX2019008949A MX2019008949A MX2019008949A MX2019008949A MX2019008949A MX 2019008949 A MX2019008949 A MX 2019008949A MX 2019008949 A MX2019008949 A MX 2019008949A MX 2019008949 A MX2019008949 A MX 2019008949A MX 2019008949 A MX2019008949 A MX 2019008949A
- Authority
- MX
- Mexico
- Prior art keywords
- prevent
- cardiomyopathy
- myocardial infarction
- fragment peptide
- heart failure
- Prior art date
Links
- 208000010125 myocardial infarction Diseases 0.000 title abstract 3
- 206010007558 Cardiac failure chronic Diseases 0.000 title abstract 2
- 208000031229 Cardiomyopathies Diseases 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
- 101100339431 Arabidopsis thaliana HMGB2 gene Proteins 0.000 abstract 4
- 102000055207 HMGB1 Human genes 0.000 abstract 4
- 108700010013 HMGB1 Proteins 0.000 abstract 4
- 101150021904 HMGB1 gene Proteins 0.000 abstract 4
- 239000012634 fragment Substances 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 206010020880 Hypertrophy Diseases 0.000 abstract 3
- 206010028594 Myocardial fibrosis Diseases 0.000 abstract 3
- 238000010171 animal model Methods 0.000 abstract 3
- 210000004413 cardiac myocyte Anatomy 0.000 abstract 3
- 230000000694 effects Effects 0.000 abstract 3
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 230000033115 angiogenesis Effects 0.000 abstract 2
- 206010056370 Congestive cardiomyopathy Diseases 0.000 abstract 1
- 201000010046 Dilated cardiomyopathy Diseases 0.000 abstract 1
- 206010058222 Hypertensive cardiomyopathy Diseases 0.000 abstract 1
- 206010048858 Ischaemic cardiomyopathy Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Marine Sciences & Fisheries (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Los presentes inventores han encontrado que los péptidos de fragmento HMGB1 que tienen una secuencia de aminoácidos particular muestra los efectos de mejora de la función cardíaca, inhibición de la hipertrofia de cardiomiocitos, inhibición de fibrosis miocárdica, y promoción de angiogénesis en un modelo animal de cardiomiopatía dilatada, los péptidos de fragmento HMGB1 particulares también muestran los efectos de mejora de la función cardíaca, inhibición de cardiomegalia, inhibición de hipertrofia de cardiomiocitos, inhibición de fibrosis miocárdica, y promoción de angiogénesis en un modelo animal de cardiomiopatía isquémica provocada por infarto al miocardio antiguo, y que los péptidos de fragmento HMGB1 particular muestran los efectos de inhibición de hipertrofia de cardiomiocitos e inhibición de fibrosis miocárdica en un modelo animal de cardiomiopatía hipertensiva. Basadas en estos descubrimientos, las composiciones farmacéuticas se proporcionan para la prevención y/o tratamiento de cardiomiopatía e infarto al miocardio antiguo e insuficiencia cardíaca crónica que resulta de los mismos, que comprende un péptido de fragmento HMGB1 que tiene una secuencia de aminoácidos particular.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017013293 | 2017-01-27 | ||
| JP2017151788 | 2017-08-04 | ||
| PCT/JP2018/002373 WO2018139562A1 (ja) | 2017-01-27 | 2018-01-26 | 心筋症、陳旧性心筋梗塞および慢性心不全の治療薬 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019008949A true MX2019008949A (es) | 2019-10-07 |
Family
ID=62979422
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019008949A MX2019008949A (es) | 2017-01-27 | 2018-01-26 | Agente terapeutico para cardiomiopatia, infarto al miocardio antiguo e insuficiencia cardiaca cronica. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11969459B2 (es) |
| EP (1) | EP3556378B1 (es) |
| JP (1) | JP7182162B2 (es) |
| KR (1) | KR102559262B1 (es) |
| CN (1) | CN110494154B (es) |
| AU (1) | AU2018213671B2 (es) |
| BR (1) | BR112019014921A2 (es) |
| CA (1) | CA3051825A1 (es) |
| ES (1) | ES3018357T3 (es) |
| MX (1) | MX2019008949A (es) |
| PL (1) | PL3556378T3 (es) |
| TW (1) | TWI805565B (es) |
| WO (1) | WO2018139562A1 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2571230C2 (ru) | 2008-04-30 | 2015-12-20 | Дженомикс Ко., Лтд. | Способ сбора функциональных клеток in vivo с высокой эффективностью |
| RU2016135937A (ru) | 2009-10-28 | 2018-12-11 | Дженомикс Ко., Лтд. | Средства для стимуляции регенерации тканей путем привлечения мезинхимных стволовых клеток и/или плюрипотентных стволовых клеток костного мозга в кровь |
| CN110494154B (zh) | 2017-01-27 | 2023-09-29 | 斯特姆里姆有限公司 | 心肌病、陈旧性心肌梗塞及慢性心力衰竭的治疗剂 |
| RU2019134382A (ru) * | 2017-04-07 | 2021-05-07 | Стемрим Инк. | Лекарственное средство для лечения фиброзного заболевания |
| CN118460462A (zh) | 2017-12-01 | 2024-08-09 | 斯特姆里姆有限公司 | 外胚层间充质干细胞及其产生方法 |
| EP3718561A4 (en) | 2017-12-01 | 2021-07-21 | Stemrim Inc. | Therapy for inflammatory bowel disease |
| US20210024594A1 (en) | 2018-02-08 | 2021-01-28 | StemRIM Inc. | Therapeutic Agent for Psoriasis |
| US12304933B2 (en) | 2018-10-05 | 2025-05-20 | StemRIM Inc. | Disease treatment drug based on mesenchymal-stem-cell mobilization |
| US20220009976A1 (en) * | 2018-10-05 | 2022-01-13 | StemRIM Inc. | Peptide Possessing Mesenchymal-Stem-Cell Mobilizing Activity |
| EP3865179B1 (en) | 2018-10-25 | 2025-07-23 | The University of Osaka | Hmgb1 derived peptide for treating or preventing a cartilage disorder |
| JP7495075B2 (ja) * | 2019-12-25 | 2024-06-04 | ロート製薬株式会社 | 高血圧性心疾患治療剤 |
| EP4147711A4 (en) * | 2020-04-20 | 2024-04-24 | Shionogi & Co., Ltd | Formulation containing hmgb1 partial peptide |
| CN113444692A (zh) * | 2021-06-29 | 2021-09-28 | 上海交通大学医学院附属第九人民医院 | 一种重组心肌细胞及其用途 |
| CN120329388B (zh) * | 2025-04-30 | 2025-09-26 | 中日友好医院(中日友好临床医学研究所) | 一种双靶点多肽及其在心衰治疗中的应用 |
Family Cites Families (96)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5238680B2 (es) | 1972-12-27 | 1977-09-30 | ||
| US4732155A (en) | 1985-08-27 | 1988-03-22 | The Children's Medical Center Corporation | Implantable chemoattractant system |
| US5658894A (en) | 1989-04-23 | 1997-08-19 | The Trustees Of The University Of Pennsylvania | Compositions for inhibiting restenosis |
| US5661127A (en) | 1995-05-01 | 1997-08-26 | The Regents Of The University Of California | Peptide compositions with growth factor-like activity |
| JP3018313B2 (ja) | 1996-02-23 | 2000-03-13 | 雪印乳業株式会社 | 骨形成促進及び骨吸収防止剤 |
| US6875753B1 (en) | 1996-03-14 | 2005-04-05 | The Governors Of The University Of Alberta | Methods for cell mobilization using in vivo treatment with hyaluronan (HA) |
| US20050101564A1 (en) | 1996-04-02 | 2005-05-12 | Pilarski Linda M. | Methods for cell mobilization using in vivo treatment with hyaluronan (HA) |
| ES2299241T3 (es) | 1998-03-17 | 2008-05-16 | Chugai Seiyaku Kabushiki Kaisha | Preventivos o remedios para enfermedades intestinales inflamatorias que contienen anticuerpos antagonistas del receptor il-6. |
| US20040031072A1 (en) | 1999-05-06 | 2004-02-12 | La Rosa Thomas J. | Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement |
| US6720340B1 (en) | 1999-07-28 | 2004-04-13 | The Board Of Trustees Of The Leland Stanford Jr. University | Nicotine receptor agonists in stem cell and progenitor cell recruitment |
| WO2001032129A2 (en) | 1999-11-05 | 2001-05-10 | Gerigene Medical Corporation | Augmentation and repair of age-related soft tissue defects |
| EP1114862A3 (de) | 1999-11-17 | 2003-08-06 | Switch Biotech Aktiengesellschaft | Verwendung von Polypeptiden oder diese kodierende Nukleinsäuren zur Diagnose oder Behandlung von Hauterkrankungen sowie ihre Verwendung zur Identifizierung von pharmakologisch aktiven Substanzen |
| AU4328801A (en) | 2000-02-24 | 2001-09-03 | Xcyte Therapies Inc | Simultaneous stimulation and concentration of cells |
| JP3421741B2 (ja) | 2000-05-18 | 2003-06-30 | 筑波大学長 | 人工骨髄、血球細胞の増殖方法 |
| US7754217B2 (en) | 2001-03-16 | 2010-07-13 | Bio3 Research Srl | HMGB1 protein inhibitors and/or antagonists for the treatment of vascular diseases |
| DE10121254A1 (de) | 2001-04-30 | 2002-11-07 | Switch Biotech Ag | MRP8/MRP14 Heterodimers oder seiner Einzelkomponenten alleine oder in Kombination zur Behandlung und/oder Prävention von Hauterkrankungen, Wunden und/oder Wundheilungsstörungen, die durch eine verringerte Menge an MRP8/MRP14 Heterodimeren gekennzeichnet sind |
| EP1390058A2 (en) | 2001-04-30 | 2004-02-25 | Switch Biotech Aktiengesellschaft | Mrp8/mrp14 heterodimer, or its individual components in combination, for treating and/or preventing skin diseases, wounds and/or wound-healing disturbances |
| JP2005512507A (ja) | 2001-05-15 | 2005-05-12 | ノース・ショア−ロング・アイランド・ジューイッシュ・リサーチ・インスティテュート | 抗炎症剤としてのｈｍｇフラグメントの使用 |
| US7220723B2 (en) | 2001-05-15 | 2007-05-22 | The Feinstein Institute For Medical Research | Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents |
| US7304034B2 (en) | 2001-05-15 | 2007-12-04 | The Feinstein Institute For Medical Research | Use of HMGB fragments as anti-inflammatory agents |
| ITMI20011986A1 (it) | 2001-09-25 | 2003-03-25 | San Raffaele Centro Fond | Metodo e composizione per l'attivazione di cellule presentanti l'antigene |
| AU2002366023B2 (en) | 2001-11-19 | 2007-10-25 | Kyowa Hakko Kirin Co., Ltd. | Drug mobilizing pluripotent stem cells from tissue into peripheral blood |
| CA2849201A1 (en) | 2001-12-07 | 2003-07-03 | Macropore Biosurgery, Inc. | Adipose-derived cell processing unit |
| FR2833609B1 (fr) | 2001-12-19 | 2004-12-03 | Natural Implant | Dispositif de prelevement cellulaire ou tissulaire en phase active et utilisations |
| ATE424416T1 (de) | 2002-07-03 | 2009-03-15 | San Raffaele Centro Fond | Die verwendung von hmgb1 zur behandlung von gewebeverletzungen und/oder zur unterstützung der gewebewiederherstellung |
| DE60327075D1 (de) | 2002-07-05 | 2009-05-20 | Univ Laval | Der entzündungsreaktionen |
| WO2004042033A2 (en) | 2002-11-01 | 2004-05-21 | The Board Of Trustees Of The Leland Stanford Junior University | Circulating stem cells and uses related thereto |
| GB0226251D0 (en) | 2002-11-11 | 2002-12-18 | San Raffaele Centro Fond | Acetylated protein |
| NZ540067A (en) | 2002-11-20 | 2007-05-31 | Critical Therapeutics Inc | A purified preparation of antibodies that specifically bind to a high mobility group box protein (HMGB) B box but do not specifically to non-B box epitopes of HMGB |
| US20040156851A1 (en) | 2002-11-20 | 2004-08-12 | Critical Therapeutics, Inc. | HMGB1 combination therapies |
| US7470538B2 (en) | 2002-12-05 | 2008-12-30 | Case Western Reserve University | Cell-based therapies for ischemia |
| CA2512512A1 (en) | 2003-01-03 | 2004-07-22 | Alcedo Biotech Gmbh | Uses of hmgb, hmgn, hmga proteins |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| WO2004075855A2 (en) | 2003-02-26 | 2004-09-10 | Biomed Solutions, Llc | Process for in vivo treatment of specific biological targets in bodily fluid |
| CA2520515C (en) | 2003-03-28 | 2012-08-28 | Universite Laval | S100 protein as neutrophil activator for alleviating neutropenia in cancer treatment |
| CN1193092C (zh) | 2003-03-28 | 2005-03-16 | 浙江大学 | 骨髓间充质干细胞分离和体外扩增培养方法 |
| US20090069227A9 (en) | 2003-04-29 | 2009-03-12 | Capogrossi Maurizio C | Use of HMGB1 to promote stem cell migration and/or proliferation |
| AU2004242091C1 (en) | 2003-05-07 | 2009-12-24 | La Jolla Institute For Molecular Medicine | Administration of hyaluronic acid to enhance the function of transplanted stem cells |
| US20050014255A1 (en) | 2003-05-29 | 2005-01-20 | Board Of Regents, The University Of Texas System | Stem cells for clinical and commercial uses |
| US20060183667A1 (en) | 2003-07-11 | 2006-08-17 | Novo Nordisk A/S | Stabilised insulin compositions |
| WO2005025604A2 (en) | 2003-09-10 | 2005-03-24 | The General Hospital Corporation | Use of hmgb and hmgb fragments to decrease specific immune response |
| CA2538763C (en) | 2003-09-11 | 2015-05-05 | Critical Therapeutics, Inc. | Monoclonal antibodies against hmgb1 |
| ITRM20040058A1 (it) | 2004-02-03 | 2004-05-03 | Marco E Bianchi | Inibitori ed antagonisti di hmgb1 in grado di regolare la proliferazione delle cellule muscolari lisce ed endoteliali. |
| JP2008507505A (ja) | 2004-07-20 | 2008-03-13 | プロヴィンシア・イタリアーナ・デッラ・コングレガチォーネ・フィリ・デッリマコラータ・コンセチォーネ−イスティトゥト・デルモパティコ・デッリマコラータ−アイ・アール・シー・シー・エス | 創傷治癒のためのｈｍｇｂ１の使用 |
| MX2007001155A (es) | 2004-07-29 | 2007-08-14 | Creabilis Therapeutics Spa | Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1. |
| KR101249287B1 (ko) | 2004-09-03 | 2013-04-01 | 크리어빌리스 쎄라퓨틱스 에스.피.에이. | 인간 및 비인간 ｈｍｇｂ１ ｂｏｘａ의 단백질분해효소내성 돌연변이 및 그들의 치료／진단 용도 |
| KR20070090890A (ko) | 2004-10-22 | 2007-09-06 | 메디뮨 인코포레이티드 | Ｈｍｇｂ1에 대한 고 친화성 항체 및 이의 사용 방법 |
| WO2007084253A2 (en) | 2005-11-28 | 2007-07-26 | Medimmune, Inc. | High affinity antibodies against hmgb1 and methods of use thereof |
| KR100593397B1 (ko) | 2004-10-27 | 2006-06-28 | 한국원자력연구소 | 중배엽 줄기세포 및/또는 ｐ 물질을 함유하는 상처 치유또는 상처 치유 촉진제, 또는 세포 치료제 |
| WO2006047820A1 (en) | 2004-11-01 | 2006-05-11 | Newsouth Innovations Pty Limited | Use of calgranulin a and b in the promotion and inhibition of mineralized tissue formation |
| ITRM20050032A1 (it) | 2005-01-21 | 2006-07-22 | Marco E Bianchi | Inibitori ed antagonisti di hmgb1 in grado di inibire la patogenesi e la progressione della malattia aterosclerotica. |
| JP5103626B2 (ja) | 2005-01-27 | 2012-12-19 | 財団法人ヒューマンサイエンス振興財団 | 間葉系幹細胞を含む細胞シート |
| US20080171951A1 (en) | 2005-03-23 | 2008-07-17 | Claude Fell | Integrated System for Collecting, Processing and Transplanting Cell Subsets, Including Adult Stem Cells, for Regenerative Medicine |
| WO2006114805A2 (en) | 2005-04-28 | 2006-11-02 | Fondazione Centro San Raffaele Del Monte Tabor | Use of hmgb2 and hmgb3 proteins for medical applications |
| US20100280493A1 (en) | 2005-06-23 | 2010-11-04 | Asha Nayak | Methods and Systems for Treating Injured Cardiac Tissue |
| WO2007011606A2 (en) | 2005-07-18 | 2007-01-25 | Critical Therapeutics, Inc. | USE OF HMGBl ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY SKIN CONDITIONS |
| WO2007015546A1 (ja) | 2005-08-04 | 2007-02-08 | Genomix Co., Ltd | 間葉系幹細胞誘導剤及び組織再生促進剤並びに間葉系幹細胞の調製方法 |
| WO2007031100A1 (en) | 2005-09-14 | 2007-03-22 | Ostini, Marco | Active immunotherapy of life-threatening systemic inflammation |
| WO2007061762A2 (en) | 2005-11-18 | 2007-05-31 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Healt And Human Services | Non-viral gene delivery complex |
| CA2640087A1 (en) | 2006-01-25 | 2007-08-02 | Mount Sinai School Of Medicine | Methods and compositions for modulating the mobilization of stem cells |
| US7829097B2 (en) * | 2006-02-06 | 2010-11-09 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Use of HMGB1 for protection against ischemia reperfusion injury |
| JP4982739B2 (ja) | 2006-06-01 | 2012-07-25 | 国立大学法人 東京医科歯科大学 | ポリグルタミン病の予防・治療剤 |
| JP5244785B2 (ja) | 2006-08-11 | 2013-07-24 | 小野薬品工業株式会社 | ストローマ由来因子−１（ｓｄｆ−１）に対するモノクローナル抗体 |
| HRP20110487T1 (hr) | 2006-09-15 | 2011-08-31 | Creabilis Therapeutics S.R.L. | Polimerni konjugati hmgb1 box-a i varijanti hmgb1 box-a |
| HUE035043T2 (en) | 2006-10-30 | 2018-05-02 | Genomix Co Ltd | A pharmaceutical composition for promoting functional regeneration of damaged tissue |
| CA2629652A1 (en) | 2007-04-24 | 2008-10-24 | Yaojiong Wu | Compositions for preventing or treating skin defects and methods of use thereof |
| US8114668B2 (en) | 2007-05-14 | 2012-02-14 | Cardiac Pacemakers, Inc. | Composition for cold storage of stem cells |
| US8673580B2 (en) | 2008-04-30 | 2014-03-18 | Genomix Co., Ltd. | Agent for recruitment of bone-marrow-derived pluripotent stem cell into peripheral circulation |
| RU2571230C2 (ru) | 2008-04-30 | 2015-12-20 | Дженомикс Ко., Лтд. | Способ сбора функциональных клеток in vivo с высокой эффективностью |
| KR20110027665A (ko) | 2008-04-30 | 2011-03-16 | 가부시키가이샤 제노믹스 | 손상조직의 기능적 재생 촉진 의약 |
| ES2609006T3 (es) | 2009-10-16 | 2017-04-18 | Rutgers, The State University Of New Jersey | Procedimeinto de tratamiento de lesión crónica de tejido nervioso usando una estrategia de terapia celular |
| WO2011049810A2 (en) | 2009-10-20 | 2011-04-28 | Maine Medical Center | Compositions and methods for treating inflammation and fibrosis |
| RU2016135937A (ru) | 2009-10-28 | 2018-12-11 | Дженомикс Ко., Лтд. | Средства для стимуляции регенерации тканей путем привлечения мезинхимных стволовых клеток и/или плюрипотентных стволовых клеток костного мозга в кровь |
| AU2011209431B2 (en) * | 2010-01-29 | 2016-09-08 | Metanomics Gmbh | Means and methods for diagnosing heart failure in a subject |
| CN102247392A (zh) | 2010-05-21 | 2011-11-23 | 中国医学科学院药物研究所 | 甘草酸治疗扩张型心肌病心脏重构和心功能障碍的用途 |
| JP5950428B2 (ja) | 2010-08-05 | 2016-07-13 | 日東電工株式会社 | 線維化組織から正常組織を再生するための組成物 |
| AU2011299025B2 (en) | 2010-09-09 | 2015-07-09 | Nationwide Children's Hospital, Inc. | Compositions and methods for the removal of biofilms |
| DK3358011T3 (da) | 2011-04-26 | 2020-05-11 | Univ Osaka | Peptid til inducering af regenerering af væv og anvendelse deraf |
| CN102443064A (zh) | 2011-11-03 | 2012-05-09 | 刘誉 | 一种基于凝血酶活性的双靶向作用的嵌合多肽及其应用 |
| ES2661500T3 (es) | 2012-07-26 | 2018-04-02 | Ospedale San Raffaele S.R.L. | Variantes de HMGB1 y sus usos |
| KR101448800B1 (ko) | 2012-10-24 | 2014-10-13 | 한양대학교 산학협력단 | 핵산 전달 복합체 |
| ES2660420T3 (es) * | 2012-10-25 | 2018-03-22 | Genomix Co., Ltd. | Método novedoso para tratar infarto cardiaco utilizando fragmento de HMGB1 |
| AU2013335685B2 (en) | 2012-10-25 | 2017-10-12 | Osaka University | Novel method for treating spinal cord injury using HMGB1 fragment |
| GB2514424A (en) * | 2013-05-25 | 2014-11-26 | Univ Dublin | Therapies for Cardiomyopathy |
| KR101636139B1 (ko) | 2013-08-28 | 2016-07-06 | 가톨릭대학교 산학협력단 | 면역조절능이 우수한 sRAGE 과발현 간엽줄기세포 및 이를 포함하는 면역질환의 예방 또는 치료용 세포치료제 조성물 |
| GB201508337D0 (en) | 2015-05-15 | 2015-06-24 | Hmgbiotech S R L | Novel peptides |
| CN110494154B (zh) | 2017-01-27 | 2023-09-29 | 斯特姆里姆有限公司 | 心肌病、陈旧性心肌梗塞及慢性心力衰竭的治疗剂 |
| RU2019134382A (ru) | 2017-04-07 | 2021-05-07 | Стемрим Инк. | Лекарственное средство для лечения фиброзного заболевания |
| EP3718561A4 (en) | 2017-12-01 | 2021-07-21 | Stemrim Inc. | Therapy for inflammatory bowel disease |
| CN118460462A (zh) | 2017-12-01 | 2024-08-09 | 斯特姆里姆有限公司 | 外胚层间充质干细胞及其产生方法 |
| US20210024594A1 (en) | 2018-02-08 | 2021-01-28 | StemRIM Inc. | Therapeutic Agent for Psoriasis |
| US12304933B2 (en) | 2018-10-05 | 2025-05-20 | StemRIM Inc. | Disease treatment drug based on mesenchymal-stem-cell mobilization |
| US20220009976A1 (en) | 2018-10-05 | 2022-01-13 | StemRIM Inc. | Peptide Possessing Mesenchymal-Stem-Cell Mobilizing Activity |
| WO2020158924A1 (ja) | 2019-01-31 | 2020-08-06 | 国立大学法人大阪大学 | 母児間免疫寛容を誘導する方法 |
| WO2021020509A1 (ja) | 2019-07-31 | 2021-02-04 | 株式会社ステムリム | 間葉系幹細胞の増殖促進または減少抑制のための組成物 |
| US20230241159A1 (en) | 2020-04-03 | 2023-08-03 | StemRIM Inc. | Peptide Having Mesenchymal Stem Cell Mobilizing Activity |
-
2018
- 2018-01-26 CN CN201880008721.3A patent/CN110494154B/zh active Active
- 2018-01-26 PL PL18745136.4T patent/PL3556378T3/pl unknown
- 2018-01-26 BR BR112019014921-0A patent/BR112019014921A2/pt unknown
- 2018-01-26 AU AU2018213671A patent/AU2018213671B2/en active Active
- 2018-01-26 EP EP18745136.4A patent/EP3556378B1/en active Active
- 2018-01-26 ES ES18745136T patent/ES3018357T3/es active Active
- 2018-01-26 KR KR1020197024762A patent/KR102559262B1/ko active Active
- 2018-01-26 JP JP2018564639A patent/JP7182162B2/ja active Active
- 2018-01-26 CA CA3051825A patent/CA3051825A1/en active Pending
- 2018-01-26 US US16/477,878 patent/US11969459B2/en active Active
- 2018-01-26 WO PCT/JP2018/002373 patent/WO2018139562A1/ja not_active Ceased
- 2018-01-26 TW TW107102933A patent/TWI805565B/zh active
- 2018-01-26 MX MX2019008949A patent/MX2019008949A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018139562A1 (ja) | 2018-08-02 |
| EP3556378C0 (en) | 2025-03-12 |
| KR102559262B1 (ko) | 2023-07-25 |
| US20190343924A1 (en) | 2019-11-14 |
| EP3556378A1 (en) | 2019-10-23 |
| JPWO2018139562A1 (ja) | 2019-11-14 |
| AU2018213671B2 (en) | 2024-06-06 |
| KR20190122212A (ko) | 2019-10-29 |
| EP3556378B1 (en) | 2025-03-12 |
| TWI805565B (zh) | 2023-06-21 |
| PL3556378T3 (pl) | 2025-06-09 |
| CA3051825A1 (en) | 2018-08-02 |
| JP7182162B2 (ja) | 2022-12-02 |
| EP3556378A4 (en) | 2020-11-18 |
| US11969459B2 (en) | 2024-04-30 |
| BR112019014921A2 (pt) | 2020-03-31 |
| RU2019126796A3 (es) | 2021-05-26 |
| ES3018357T3 (es) | 2025-05-16 |
| TW201832776A (zh) | 2018-09-16 |
| AU2018213671A1 (en) | 2019-08-08 |
| CN110494154A (zh) | 2019-11-22 |
| CN110494154B (zh) | 2023-09-29 |
| RU2019126796A (ru) | 2021-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019008949A (es) | Agente terapeutico para cardiomiopatia, infarto al miocardio antiguo e insuficiencia cardiaca cronica. | |
| CY1124309T1 (el) | Τροποποιημενα πολυπεπτιδια fgf-21 και χρησεις εξ αυτων | |
| PE20191551A1 (es) | Polipeptidos de union al receptor de transferrina disenados | |
| PE20170471A1 (es) | Polipeptidos receptores formulados y metodos relacionados | |
| PH12018502361B1 (en) | Gdf15 fusion proteins and uses thereof | |
| AR106753A1 (es) | Proteínas de unión a ctla4p | |
| PE20170771A1 (es) | Composiciones y metodos de uso para tratar trastornos metabolicos | |
| PE20161442A1 (es) | Proteinas quimericas tipo fosfatasa alcalina | |
| WO2015191781A3 (en) | Apelin polypeptides | |
| MX2017009595A (es) | Compuestos antisenescentes y usos de los mismos. | |
| MX2021000030A (es) | Metodos y composiciones que utilizan polipeptidos variantes klotho. | |
| WO2016115511A3 (en) | Vegf variant polypeptide compositions | |
| AR120721A2 (es) | Péptidos y composiciones para el tratamiento de daño articular | |
| BR112017013300A2 (pt) | alfa galactosidase a recombinante e/ou fragmento de alfa galactosidase a recombinante biologicamente ativo, composição, sequência de polinucleotídeos recombinantes, vetor de expressão, célula hospedeira, métodos para produzir uma variante de alfa galactosidase a e para tratar e/ou prevenir os sintomas da doença de fabry, composição farmacêutica, e, uso das composições. | |
| PE20161406A1 (es) | Proteinas de fusion tatk-cdkl5, composiciones, formulaciones y uso de estas | |
| BR112013025975A2 (pt) | proteína de fusão anticancerígena | |
| JP2016515123A5 (es) | ||
| BR112016021000A2 (pt) | Composições e métodos para prevenir ou tratar dis-função crônica do aloenxerto de pulmão (clad) e fi-brose pulmonar idiopática (ipf) | |
| WO2017180988A3 (en) | Fgf21 c-terminal peptide optimization | |
| MY187334A (en) | Xylanase | |
| NZ732301A (en) | Peptide compound, preparation method therefor, and application thereof | |
| MX2017008505A (es) | Composicion. | |
| CO2019012204A2 (es) | Proteínas de unión al antígeno anti-jagged1 | |
| JP2017517561A5 (es) | ||
| MX380750B (es) | Composición farmacéutica para tratar y/o prevenir el cáncer. |